Fig. 3: Association of pretreatment circulating T cell populations with MPR (≤90% residual viable tumor cells).

A PaCMAP projection and FlowSOM clustering of CD4+ T cells from all PBMC samples. Heatmap overlays indicates relative expression for each phenotypic marker. Tnv = naïve T cell phenotype, T_reg = regulatory T cell phenotype, T_em = effector memory T cell phenotype, T_cm = central memory T cell phenotype. In all panels, patients are stratified by percent tumor regression: those with ≥90% tumor regression (defined clinically as major pathological response) and those with <90% tumor regression. Comparison between treatment arms shown in panels (B, D, G, I, K, M). Comparison between MPR and no MPR regardless of treatment arm shown in panels (C, E, H, J, L, N). B, C Frequency of CD4_P1 (CD103-expressing) T cell population in PBMC samples. D, E Frequency of CD103+/CD4+ T cells in PBMC samples measured by manual gating. F PaCMAP projection and FlowSOM clustering of CD8+ T cells from all PBMC samples. Heatmap overlays indicates relative expression for each phenotypic marker. Tnv = naïve T cell phenotype, T_emra = terminal effector T cell phenotype, T_em = effectory memory T cell phenotype, T_cm = central memory T cell phenotype. G, H Frequency of CD8_P7 (CD103-expressing) T cell population in PBMC samples. I, J Frequency of CD103+/CD8+ T cells in PBMC samples measured by manual gating. K, L Combined per-patient frequency of CD8_P7 and CD4_P1 T cell populations in PBMC samples. M, N Frequency of PD1+ T cells in PBMC samples measured by manual gating. All panels, two-tailed Mann-Whitney test. Panels (B, D, G, I, K, M) Durva <90% (n = 13); Durva + SBRT < 90% (n = 8); Durva ≥90% (n = 0); Durva + SBRT, ≥90% (n = 8). Panels (C, E, H, J, L, N): <90% (n = 21); ≥90% (n = 8). Source data for all panels are provided as a Source Data file.